Every 8-K that Mesa Laboratories Inc (MLAB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MLAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MLAB filings page.
MESA LABORATORIES, INC. (MLAB) reported the results of its September 8, 2026 annual meeting of shareholders. Holders of 5,595,869 common shares were entitled to vote, and 4,872,692 shares were represented in person or by proxy.
All seven director nominees — John Sullivan, Siddhartha Kadia, Shiraz Ladiwala, Jennifer “Jenny” Alltoft, Mark Capone, Shannon Hall, and R. Tony Tripeny — were elected to one-year terms, each receiving over 4.35 million votes in favor, with broker non-votes recorded. Shareholders also approved the ratification of Baker Tilly US, LLP as independent registered public accounting firm for the fiscal year ending March 31, 2027, with 4,814,383 votes for. On a non-binding advisory basis, shareholders approved the compensation of the named executive officers, with 4,317,389 votes for and 136,782 against.
Mesa Laboratories, Inc. reported first fiscal quarter 2027 results for the three months ended June 30, 2026. Revenues were $60,138 thousand, up 1.0% year over year, with growth in Biopharmaceutical Development and Calibration Solutions partly offset by declines in Sterilization and Disinfection Control and essentially flat Clinical Genomics.
Operating income rose 129% to $7,031 thousand as gross profit improved and operating expenses declined. However, net income was $2,830 thousand, down 40.3%, or $0.49 per diluted share, mainly due to nonoperating expense of $2,678 thousand versus nonoperating income of $3,948 thousand in the prior year, which had included approximately $6,150 thousand of unrealized foreign currency gains.
Non-GAAP Adjusted Operating Income (AOI) increased 16.5% to $15,035 thousand, or $2.61 per diluted share, and AOI excluding unusual items (a $382 thousand legal settlement) was $15,417 thousand, up 19.5%. The company repaid $8,656 thousand of debt, bringing its Total Net Leverage Ratio to 1.85, below its stated target of 2.0. Management emphasized disciplined execution, capital allocation and plans to provide full-year guidance in November.
Mesa Laboratories, Inc. reported that its Board of Directors approved an amended and restated Code of Ethics and Business Conduct on July 30, 2026, effective immediately. The updated Code replaces the prior version.
The amendments are described as updating and modernizing the Code, including specific revisions related to external communications and social media, along with other clarifying, administrative, compliance and procedural updates. The complete Code of Ethics and Business Conduct is provided as Exhibit 14.1 to the report.
Mesa Laboratories appointed Lyndsey Crennen as Chief Accounting Officer, effective upon entry into a new Employment Agreement. She has over 20 years of accounting experience and has served in progressively senior roles at Mesa since 2018, including Corporate Controller since 2022.
Under the expected Employment Agreement, Crennen will receive a base salary of $325,000, be eligible for an annual cash bonus equal to 40% of base salary under the short-term incentive plan, and have a long-term incentive target award value of $300,000. The agreement includes customary severance and other terms, and the company states there are no related-party transactions or family relationships requiring disclosure.
Mesa Laboratories reported modest growth for its fourth quarter and full fiscal year 2026 ended March 31, 2026. Quarterly revenues were $63,724, up 2.6% year over year, with strong Sterilization and Disinfection Control growth offset by a sharp decline in Biopharmaceutical Development.
For FY26, revenues reached $249,130, a 3.4% increase, while net income improved to $6,712, or $1.21 per diluted share, compared with a prior-year loss. Non-GAAP adjusted operating income excluding unusual items rose 11.9% to $63,487, representing a 25.5% margin. Free cash flow was $39,581, allowing the company to reduce its Total Net Leverage Ratio to 2.11.
Mesa Laboratories detailed the transition of President and CEO Gary Owens, whose departure was previously announced and will be effective on or about April 13, 2026. Under a new Retention and Transition Agreement dated March 20, 2026, he will continue in a non-executive role until June 22, 2026 to support an orderly handover.
At his June 22, 2026 separation, Mr. Owens will receive severance pay and benefits consistent with a “without cause” termination and keep a pro-rated portion of his June 15, 2025 performance stock unit award, vesting at the lower of target or actual performance. He must sign a release of claims to receive these benefits. He also resigned from the board as of March 20, 2026, and the company states his resignation was not due to any disagreement over operations, policies, or practices.
Mesa Laboratories is making a planned leadership change. Gary Owens will step down as President and CEO around April 12–13, 2026, with the company stating his departure is not due to any disagreement over operations, policies, or practices.
The Board has appointed Dr. Siddhartha Kadia as the new President and CEO and as a director, effective April 13, 2026. Under his employment agreement, he will receive an annual base salary of $850,000, a target annual bonus equal to at least 100% of salary, and initial equity awards of RSUs valued at $3.0 million and PSUs with a target value of $3.0 million, subject to multi‑year vesting and performance conditions.
Mesa Laboratories, Inc. filed a current report to let investors know it has released financial results. On February 3, 2026, the company issued a press release covering its performance for the three and nine months ended December 31, 2025.
The press release is included as Exhibit 99.1 and is provided as supplemental information. The company specifies that this earnings information is being furnished, not filed, which means it is not subject to certain liability provisions of the securities laws or automatically incorporated into other securities offerings.
Mesa Laboratories (MLAB) announced it issued a press release covering results for the three and six months ended September 30, 2025. The company furnished the press release as Exhibit 99.1 to this Form 8‑K.
The information provided with the press release is being furnished, not filed, which means it is not subject to Section 18 liabilities and is not incorporated by reference into Securities Act filings. The filing lists MLAB common stock on The Nasdaq Stock Market LLC.
Mesa Laboratories, Inc. held its annual meeting on August 22, 2025. Holders of 5,501,454 shares were entitled to vote and 5,203,377 shares were represented in person or by proxy. Seven director nominees — John J. Sullivan, Gary M. Owens, Jennifer S. Alltoft, Shannon M. Hall, Shiraz S. Ladiwala, R. Tony Tripeny and Mark C. Capone — were each elected to one-year terms through the 2026 annual meeting. The board then appointed committee members. Shareholders ratified Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026. On a non-binding advisory basis, shareholders approved the compensation of the company’s named executive officers as disclosed in the proxy statement.
Mesa Laboratories, Inc. drew $97 million under its existing senior secured Credit Facility on August 12, 2025, bringing total outstanding borrowings under that facility to $108 million. The company used the proceeds to fund settlement of its outstanding convertible notes that matured on August 15, 2025, in accordance with the indenture.
The Credit Facility carries interest at either a base rate or a SOFR rate plus a spread and matures on April 5, 2029. The filing references the full credit agreement previously filed on April 8, 2024, and includes a press release as Exhibit 99.1 dated August 18, 2025.
On August 5, 2025, Mesa Laboratories, Inc. (Ticker: MLAB) filed a Form 8-K reporting that it issued a press release relating to its results for the three months ended June 30, 2025. The press release is furnished as Exhibit 99.1 to the Form 8-K.
The Form 8-K states that the information furnished in Item 2.02 and Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act and shall not be incorporated by reference into registration statements under the Securities Act. The filing also lists Exhibit 104 (Cover Page Interactive Data File). The report is signed by Gary M. Owens, President and Chief Executive Officer, dated August 5, 2025, and includes the registrant address and Nasdaq listing (symbol MLAB).